Commodore Capital LP
Commodore Capital LP reported 37 holdings worth US$1.29B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Commodore Capital LP reported 37 holdings worth US$1.29B as of Sep 30, 2026. Largest: Relay Therapeutics, Inc., Enliven Therapeutics, Inc. and Alto Neuroscience, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 37
- Value as reported
- US$1.29B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Relay Therapeutics, Inc. | 12M | US$217M | 16.8% |
| Enliven Therapeutics, Inc. | 3.27M | US$150M | 11.6% |
| Alto Neuroscience, Inc. | 2.72M | US$69.5M | 5.4% |
| Spyre Therapeutics, Inc. | 700K | US$62.3M | 4.8% |
| Amylyx Pharmaceuticals, Inc. | 2M | US$58.2M | 4.5% |
| LB Pharmaceuticals Inc | 1.28M | US$49.2M | 3.8% |
| Cogent Biosciences, Inc. | 1.26M | US$40.5M | 3.1% |
| Tyra Biosciences, Inc. | 1.73M | US$37.7M | 2.9% |
| Celldex Therapeutics, Inc. | 1M | US$32.4M | 2.5% |
| Surrozen, Inc. | 885K | US$28.5M | 2.2% |
| Sagimet Biosciences Inc. - Series A | 2.76M | US$27.2M | 2.1% |
| Definium Therapeutics, Inc. | 700K | US$26.6M | 2.1% |
| ADARx Pharmaceuticals, Inc. | 1.26M | US$25.1M | 1.9% |
| Editas Medicine, Inc. | 8.89M | US$22.8M | 1.8% |
| Attovia Therapeutics, Inc. | 1.16M | US$19.9M | 1.5% |
| Agenus Inc. | 1.99M | US$19.7M | 1.5% |
| Kymera Therapeutics, Inc. | 175K | US$19.6M | 1.5% |
| Avalo Therapeutics, Inc. | 1.02M | US$15.6M | 1.2% |
| AN2 Therapeutics, Inc. | 2.93M | US$15.6M | 1.2% |
| Century Therapeutics, Inc. | 8.7M | US$14.9M | 1.2% |
| Zura Bio Limited | 3.25M | US$13.5M | 1.0% |
| Inhibikase Therapeutics, Inc. | 5.4M | US$11.1M | 0.86% |
| Assembly Biosciences, Inc. | 462K | US$10.9M | 0.84% |
| PepGen Inc. | 4.47M | US$10.8M | 0.84% |
| SAB Biotherapeutics, Inc. | 2.87M | US$9.1M | 0.70% |
| Relmada Therapeutics, Inc. | 2.35M | US$8.86M | 0.69% |
| Research Alliance Corporation IV | 500K | US$5.79M | 0.45% |
| Helix Acquisition Corp. III | 500K | US$5.31M | 0.41% |
| JATT III Acquisition Corp | 400K | US$4.41M | 0.34% |
| TCGX Acquisition Corp. | 300K | US$3.75M | 0.29% |
| LeonaBio, Inc. | 464K | US$1.66M | 0.13% |
| Vistagen Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Damora Therapeutics, Inc. | 0 | US$0 | 0.00% |
| EyePoint, Inc. | 0 | US$0 | 0.00% |
| Nuvalent, Inc. | 0 | US$0 | 0.00% |
| Perspective Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Research Alliance Corporation III | 0 | US$0 | 0.00% |
| Tango Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related